A number of investment brokers have recently updated their price targets on shares of Cellular Dynamics International, Inc. (NASDAQ:ICEL).
Most recent broker ratings
04/14/2015 – Cellular Dynamics International, Inc. was downgraded to “mkt perform” by analysts at Leerink Swann. They now have a USD 16.5 price target on the stock.
03/31/2015 – Cellular Dynamics International, Inc. was downgraded to “market perform” by analysts at Cowen.
The share price of Cellular Dynamics International, Inc. (NASDAQ:ICEL) was up +0.00% during the last day of trading, with a day high of 0.00. 0 shares were traded during the last session.
The stock’s 50 day moving average is 14.00 and its 200 day moving average is 8.00.Cellular Dynamics International, Inc. has a 52-week low of 5.00 and a 52-week high of 17.00.
Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.